Today: 22 May 2026
Browse Category

CSE:APXC 19 January 2026

Stock Market Today

  • Special Dividends Boost Mini-Portfolio Yield from 6% to 10%
    May 22, 2026, 10:18 AM EDT. Special dividends-one-time or supplemental payouts-often go unreported on typical finance websites, causing investors to underestimate actual yields. This is evident in a mini-portfolio including retailers Dillard's (DDS) and The Buckle (BKE). Mainstream sites list Dillard's dividend yield as 0.2%, ignoring large special dividends paid annually (up to $30 per share in 2025), lifting its true yield to 5.9%. The Buckle's regular yield stands near 3%, but large recent special dividends significantly increase the yield. Collectively, this seven-stock set, commonly reported at a 6% yield, actually delivers closer to 10%, with some payers reaching up to 14.6%. Investors relying solely on vanilla dividend research may overlook substantial income potential from these overlooked special dividends.

Latest articles

Archer Aviation Rises as Air-Taxi Hopes Return

Archer Aviation Rises as Air-Taxi Hopes Return

22 May 2026
Archer Aviation stock traded at $6.14 in premarket Friday after jumping 5.8% Thursday on heavy volume, as investors watched FAA certification progress for its Midnight eVTOL aircraft. Archer reported a Q1 net loss of $217.7 million and ended March with $1.78 billion in cash. The company expects initial U.S. operations in 2026 under a federal pilot program. S&P 500 and Nasdaq futures were higher before the open.
UP Fintech Shares Drop in Premarket After Crackdown on Tiger Brokers in China

UP Fintech Shares Drop in Premarket After Crackdown on Tiger Brokers in China

22 May 2026
UP Fintech’s Nasdaq-listed shares fell 34.47% to $3.83 in premarket trading after China’s securities regulator said its Tiger Brokers unit, Futu, and Longbridge operated unlicensed cross-border securities businesses for mainland investors. The regulator plans to confiscate illegal gains and impose penalties. UP Fintech is set to report first-quarter results on June 2.
Akari Therapeutics Shares Jump As KRAS Cancer News Returns

Akari Therapeutics Shares Jump As KRAS Cancer News Returns

22 May 2026
Akari Therapeutics shares more than doubled in premarket trading Friday after its lead cancer drug showed positive preclinical results in KRAS-mutated pancreatic cancer models and the company announced a $5.5 million private placement. The stock was quoted at $10.15, up from Thursday’s $5.14 close. Akari plans to start Phase 1 human trials of AKTX-101 by mid-2027. The company reported $2.8 million in cash at March 31.
Go toTop